University of Pittsburgh v. Cook Myosite: skMDC Cell Patent Dispute Settles After 1,056 Days
The University of Pittsburgh asserted US8211423B2 — a patent covering skeletal muscle-derived cell (skMDC) technology — against Cook Myosite, Inc. in the Western District of Pennsylvania. The case, filed in May 2022, resolved via confidential settlement in April 2025, after nearly three years of litigation spanning infringement claims and counterclaims.
Academic IP Meets Regenerative Medicine: Pitt vs. Cook Myosite
The University of Pittsburgh filed this patent infringement action on May 13, 2022 in the Western District of Pennsylvania against Cook Myosite, Inc., a biologics company focused on skeletal muscle-derived cell therapies. At the center of the dispute is US8211423B2, a patent covering skMDC (skeletal muscle-derived cell) compositions and related technology — an area of significant clinical and commercial interest in regenerative medicine and cell therapy.
After 1,056 days of litigation — including infringement claims by the University and counterclaims by Cook Myosite — the parties announced on or around April 3, 2025 that they had reached a confidential agreement in principle. The case settled before any publicly reported trial or merits judgment. A stipulation of dismissal or joint status report was required by April 17, 2025, consistent with standard Western District of Pennsylvania settlement procedure.
The extended timeline — nearly three years — suggests the dispute involved substantive technical and commercial complexity, potentially including claim construction, validity challenges, and damages discovery related to a specialized cell therapy product line. The confidential nature of the resolution means licensing terms, royalty arrangements, or any ongoing collaboration between the parties remain unknown from the public record. The involvement of multiple large law firms on both sides is consistent with high-stakes IP enforcement in the biotech sector.
Filing to Case Settled in 1056 days
1,056 days — notably long for a district court patent case; median patent suit resolves in roughly 700–900 days
Confidential settlement: what the resolution means for both parties
What a confidential settlement means in patent litigation
A settlement in principle terminates all pending claims and counterclaims without a court ruling on the merits. The parties agree to resolve the dispute privately, with terms — such as licensing fees, royalties, or product restrictions — kept out of the public record. A formal stipulation of dismissal typically follows, formally closing the docket. No finding of infringement or invalidity is entered by the court.
No merits rulingUniversity of Pittsburgh: IP enforced, terms undisclosed
For the University of Pittsburgh, a settlement — particularly after nearly three years of litigation — typically signals that it extracted value from enforcement, whether through a licensing arrangement, royalty stream, or agreed product restrictions. US8211423B2 remains an issued, unchallenged patent on the public record, as no invalidity finding was made. The University’s willingness to settle rather than proceed to trial may reflect risk management around damages or claim scope uncertainty.
Patent survivesCook Myosite avoids a public infringement finding
Cook Myosite resolves the case without any court-entered finding of infringement, which is commercially significant for a company active in cell therapy markets where IP freedom-to-operate is closely scrutinised. The confidential terms may include a license, product design changes, or a lump-sum payment. Cook Myosite’s counterclaims — the nature of which are not fully disclosed — were also resolved, suggesting a comprehensive bilateral resolution.
No infringement findingSettlement preserves uncertainty in skMDC patent landscape
Because the case settled confidentially, the scope and validity of US8211423B2 were never adjudicated. This preserves commercial uncertainty for other companies operating in the skeletal muscle-derived cell therapy space — they cannot rely on a court ruling to assess their own FTO position relative to this patent. Competitors and new entrants should treat US8211423B2 as an active enforcement risk and conduct independent FTO analysis.
FTO risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | The University of Pittsburgh of The Commonwealth System of Higher Education | Company | University biotech IP licensor — holder of US8211423B2 covering skMDC cell technologySearch in Eureka ↗ |
| Defendant | Cook Mysite, Inc. | Company | Cook Myosite, Inc. — biologics company commercialising skeletal muscle-derived cell therapiesSearch in Eureka ↗ |
| Plaintiff counsel | Alison Siedor | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Colin J. Callahan | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Cristina Denise Go | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Grace Truong | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Huiya Wu | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy Knight | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Madeline Bordynoski | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Olubukola Ayetiwa | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Shannon Huygens | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff counsel | Shovon Ashraf | Attorney | Counsel for The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff law firm | Flannery Georgalis | Law Firm | Representing The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff law firm | Goodwin Procter LLP | Law Firm | Representing The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Plaintiff law firm | Littler Mendelson | Law Firm | Representing The University of Pittsburgh of The Commonwealth System of Higher EducationSearch in Eureka ↗ |
| Defendant counsel | Ahmad Haroon Malik | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Alison Baldwin | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrea Savageau | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrew McCoy | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Kevin M. Eddy | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Laura Lydigsen | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew James Spegele | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | R. Trevor Carter | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Raija J Horstman | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Ryan Henry Seewald | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Valerie Goo | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant counsel | Victoria D. Summerfield | Attorney | Counsel for Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant law firm | Blank Rome LLP | Law Firm | Representing Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant law firm | Crowell & Moring LLP | Law Firm | Representing Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant law firm | Faegre Drinker Biddle & Reath LLP | Law Firm | Representing Cook Mysite, Inc.Search in Eureka ↗ |
| Defendant law firm | Troutman Pepper Hamilton Sanders LLP | Law Firm | Representing Cook Mysite, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Christy Criswell Wiegand | Judge | Pennsylvania Western District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict notice confirms a bilateral resolution — both infringement claims and Cook Myosite’s counterclaims are resolved under a single confidential agreement. The phrasing ‘agreement in principle’ is notable: it indicates the commercial deal was struck but formal documentation was pending, with a hard deadline of April 17, 2025 for filing. No merits determination was made, meaning neither infringement nor invalidity of US8211423B2 was adjudicated. For both parties, the settlement represents a negotiated exit from substantive litigation risk.
US8211423B2 — Skeletal Muscle-Derived Cell (skMDC) Compositions
US8211423B2 (application number US11/998330) is a granted US patent covering compositions and related technology derived from skeletal muscle cells — specifically the skMDC (skeletal muscle-derived cell) platform. This patent originates from University of Pittsburgh research, consistent with the institution’s significant output in regenerative medicine and cell-based therapies. Skeletal muscle-derived cells have been explored for applications including urinary incontinence treatment, muscle repair, and broader regenerative indications, giving the patent potential clinical and commercial breadth.
For competitors and technology developers in the cell therapy space, US8211423B2 represents a foundational academic patent that has now demonstrated active enforcement value — the University pursued litigation for nearly three years and reached a settlement with a commercial operator. Companies developing autologous or allogeneic muscle-derived cell products, or working on adjacent applications such as pelvic floor or cardiac muscle repair, should assess whether their technology, manufacturing processes, or product compositions fall within the claim scope of this patent. The absence of any invalidity ruling further strengthens its standing.
Should your team run an FTO analysis against US8211423B2?
Any company developing, manufacturing, or commercialising skeletal muscle-derived cell (skMDC) products — including cell therapy platforms for urological, orthopaedic, or regenerative indications — should treat US8211423B2 as a live FTO concern. The University of Pittsburgh’s willingness to litigate for nearly three years signals active enforcement intent, and the patent’s survival without any invalidity finding means it retains full enforceability. This is particularly relevant for companies entering or scaling in the US cell therapy market.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map product candidates and manufacturing processes against the claims of US8211423B2 systematically, identifying potential overlap and design-around opportunities. Eureka can also surface the prosecution history, citation network, and any related continuation or divisional patents in the University of Pittsburgh portfolio — giving your team a complete picture of the enforcement landscape before committing to clinical or commercial scale-up in the skMDC space.
Run a freedom-to-operate analysis on US8211423B2 to assess your product’s exposure
Run FTO in Eureka →Similar Patent Cases: Skeletal Muscle Cell & Regenerative Biotech Disputes
Explore comparable infringement actions involving cell therapy and regenerative medicine patents litigated in federal district courts, including W.D. Pennsylvania.
What this case signals for the cell therapy IP landscape
A major research university enforcing a core cell biology patent against a commercial biotech raises implications well beyond this single dispute.
University IP enforcement in cell therapy is a real and active risk
This case confirms that major research universities actively monitor and enforce foundational cell biology patents against commercial operators. Companies licensing or commercialising skeletal muscle-derived cell products — whether for urological, orthopaedic, or other indications — should map their product IP against academic patent portfolios, particularly those originating from major research institutions like the University of Pittsburgh.
No merits ruling leaves US8211423B2 fully enforceable
Because the case settled without any court finding on validity or infringement, US8211423B2 retains full legal force. Competitors in the skMDC or broader skeletal muscle-derived cell therapy sector cannot rely on this litigation outcome to justify design-arounds or non-infringement positions. An independent FTO analysis against the asserted claims of this patent is essential before entering or expanding in this product space.
The v Cook — key questions answered
The University of Pittsburgh asserted US8211423B2, a patent covering skeletal muscle-derived cell (skMDC) compositions and related technology. The case was filed in the Western District of Pennsylvania on May 13, 2022. Cook Myosite’s skMDC Skeletal Muscle-Derived Cells products were identified as the accused products.
The case settled confidentially. On or around April 3, 2025, the parties announced an agreement in principle that would resolve all claims and counterclaims. The settlement terms are not public. A stipulation of dismissal or joint status report was due by April 17, 2025. No court ruling on infringement or invalidity was entered.
The case lasted 1,056 days, from filing on May 13, 2022 to closure on April 3, 2025. This duration — nearly three years — is toward the longer end for district court patent cases and suggests substantive litigation activity including likely claim construction proceedings and damages discovery.
No. Because the case settled without any court ruling on the merits, US8211423B2 remains a fully issued and enforceable patent. No finding of invalidity, unenforceability, or non-infringement was entered. Third parties cannot rely on this litigation outcome to assess their own freedom-to-operate position relative to this patent.
Cook Myosite’s skMDC (Skeletal Muscle-Derived Cells) products are cell therapy preparations derived from skeletal muscle tissue, developed for regenerative and therapeutic applications. The University of Pittsburgh alleged these products infringed US8211423B2, which covers skeletal muscle-derived cell compositions originating from university research. The specific infringement theory and accused product details were not publicly adjudicated due to the confidential settlement.
PatSnap Eureka searches patents and litigation data to answer instantly.